RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE ...

The Guildford, England-based liquid biopsy company is presenting the new test results at the American Association for Cancer Research's Special Conference, 'Liquid Biopsy: From Discovery to Clinical ...

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

Medicaid expansion was associated with a slower decrease in receipt of guideline-concordant treatment, reduced delays in treatment initiation, and improved 2-year survival, according to researchers.

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good afternoon and welcome to Oncolytics Biotech’s Third Quarter 2024 Conference Call. All participants are in a listen-only mode. There ...

“Onco360 is grateful for the opportunity to partner with the team at Genentech and become a specialty pharmacy provider for Itovebi ™ ,” said Benito Fernandez. “We are proud to add another treatment ...

October 2024, saw significant FDA actions and clinical trial updates that shaped cancer treatment progress. Highlights include acalabrutinib’s approval for mantle cell lymphoma, T-DXd’s priority ...

Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01, 2008. The article is based primarily on a ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...